https://staging.hayatx.com/news-item/putting-innovation-at-the-heart-of-rna-based-therapeutics/ 2025-10-16T08:23:17+00:00 https://staging.hayatx.com/news-item/reprogramming-the-software-of-the-cell-to-fight-disease/ 2025-10-16T08:30:02+00:00 https://staging.hayatx.com/news-item/haya-therapeutics-wins-the-top-prize-at-the-top-100-swiss-startup-award-2023/ 2025-10-16T08:31:09+00:00 https://staging.hayatx.com/news-item/junk-dna-how-the-dark-genome-is-changing-rna-therapies/ 2025-10-16T08:31:39+00:00 https://staging.hayatx.com/news-item/the-mystery-of-the-human-genomes-dark-matter/ 2025-10-16T08:31:55+00:00 https://staging.hayatx.com/news-item/rna-companies-to-watch-over-the-next-12-months/ 2025-10-16T08:32:07+00:00 https://staging.hayatx.com/news-item/drug-discovery-startups-set-to-take-off/ 2025-10-16T08:32:32+00:00 https://staging.hayatx.com/news-item/clarivate-identifies-seven-innovators-in-new-rna-technology-companies-to-watch-report/ 2025-10-16T08:32:51+00:00 https://staging.hayatx.com/news-item/18-european-techbio-startups-to-watch-according-to-investors/ 2025-10-16T08:33:22+00:00 https://staging.hayatx.com/news-item/haya-therapeutics-sur-la-piste-de-la-fibrose/ 2025-10-16T08:33:44+00:00 https://staging.hayatx.com/news-item/what-dark-matter-means-for-the-future-of-therapeutics/ 2025-10-16T08:35:34+00:00 https://staging.hayatx.com/news-item/delivery-safety-top-concerns-as-bio-europe-plumbs-future-of-gene-therapy/ 2025-10-16T08:37:39+00:00 https://staging.hayatx.com/news-item/a-new-rna-startup-looks-to-reimagine-heart-treatments-with-eyes-set-on-entresto/ 2025-10-16T08:38:05+00:00 https://staging.hayatx.com/news-item/biotech-haya-therapeutics-shouts-hiya-as-it-emerges-from-stealth-with-seed-funding/ 2025-10-16T08:38:49+00:00 https://staging.hayatx.com/news-item/haya-therapeutics-raises-chf-18-million-seed-financing-to-advance-anti-fibrotic-therapies-targeting-long-non-coding-rnas/ 2025-10-16T08:39:11+00:00 https://staging.hayatx.com/news-item/haya-renbio-launch-with-sights-set-on-clinic/ 2025-10-16T08:40:10+00:00 https://staging.hayatx.com/news-item/eli-lilly-bets-1b-in-biobucks-on-haya-to-scour-dark-genome-for-obesity-targets/ 2025-10-16T08:44:26+00:00 https://staging.hayatx.com/news-item/lilly-inks-obesity-deal-with-seed-stage-rna-startup-as-its-genetic-medicines-effort-enters-the-spotlight/ 2025-10-16T08:46:20+00:00 https://staging.hayatx.com/news-item/haya-lilly-launch-up-to-1b-metabolic-collaboration/ 2025-10-16T08:50:06+00:00 https://staging.hayatx.com/news-item/haya-therapeutics-secures-usd-1-billion-deal-with-lilly-to-target-obesity-through-rna-platform/ 2025-10-16T08:52:05+00:00 https://staging.hayatx.com/news-item/haya-therapeutics-65m-series-a-will-bring-lncrna-targeting-drugs-to-clinic/ 2025-10-16T08:54:31+00:00 https://staging.hayatx.com/news-item/haya-therapeutics-gets-65m-for-dark-genome-work-following-last-years-lilly-pact/ 2025-10-16T08:56:17+00:00 https://staging.hayatx.com/news-item/haya-therapeutics-secures-65-million-series-a-to-advance-rna-guided-therapies-for-chronic-and-age-related-diseases/ 2025-10-16T08:59:35+00:00 https://staging.hayatx.com/news-item/startup-haya-hauls-in-65m-to-shed-light-on-the-dark-genome-with-a-lead-drug-for-heart-failure/ 2025-10-16T09:01:54+00:00 https://staging.hayatx.com/news-item/interview-with-samir-ounzain-ceo-scientific-co-founder-haya-therapeutics/ 2025-10-16T12:33:40+00:00 https://staging.hayatx.com/news-item/interview-with-eric-adam/ 2025-10-16T12:35:22+00:00 https://staging.hayatx.com/news-item/haya-therapeutics-among-wefs-2025-technology-pioneers/ 2025-10-16T15:50:22+00:00 https://staging.hayatx.com/news-item/hayas-ceo-recognized-as-one-of-the-top-innovators-by-the-medicine-maker-power-list-2025/ 2025-10-16T15:51:20+00:00 https://staging.hayatx.com/news-item/hayas-ceo-samir-ounzain-recognized-as-2025-emerging-pharma-leader/ 2025-10-16T15:55:19+00:00 https://staging.hayatx.com/news-item/samir-ounzain-hayas-ceo-recognized-as-one-of-the-100-personalities-shaping-french-speaking-switzerland/ 2025-10-23T08:53:24+00:00